Ju, Xiaotian
Son, Kiho
Jamil, Rameen
Culgin, Sarah
Salter, Brittany
Miyasaki, Kate
Fard, Nahal Emami
Xiao, Maria
Patel, Zil
Zhang, Kayla
Cowbrough, Braeden
Kjarsgaard, Melanie
Radford, Katherine
Dvorkin-Gheva, Anna
Richards, Carl D.
Cox, Gerard
Chagla, Zain
Smieja, Marek
Tunks, Marcel
Alhazzani, Waleed
Bowdish, Dawn M.E.
Perri, Dan
Nair, Parameswaran K.
Sehmi, Roma
Mukherjee, Manali
Funding for this research was provided by:
Hamilton Academic Health Sciences Organization (HAH-21-05)
Article History
Received: 21 February 2023
Accepted: 11 June 2023
First Online: 4 July 2023
Declarations
:
: The 47 patients included in the study analysis provided verbal consent (patient or appropriate surrogate) (Hamilton Integrated Research Ethics Board #10771, 11279).
: MM is supported by early investigator award from Canadian Institutes of Health Research (CIHR) and Canadian Asthma Allergy and Immunology Foundation (CAAIF). MM reports grants from CIHR, grants from Methapharm Specialty Pharmaceuticals, personal fees from AstraZeneca, GlaxoSmithKline, consultant fees from Novartis, Respiplus, outside the submitted work. MM reports being invited expert consultant on Canada Science Advisor’s Post Covid-19 Condition Taskforce. DB reports grants from COVID-19 Immunity Task Force / Public Health Agency of Canada, grants from National Science and Engineering Research Council (NSERC), grants from Canadian Institutes of Health Research, personal fees from AZ Mexico, personal fees for invited presentations from academic institutions, outside the submitted work. DB reports being on the board of directors for Lung Health Foundation and being an expert witness testimony for the Government of Canada. PN reports grants and personal fees from AZ, grants and personal fees from Teva, grants and personal fees from Sanofi, personal fees from GSK, personal fees from Equillium, personal fees from Arrowhead pharma, grants from Foresee, grants from Cyclomedica, outside the submitted work. All other authors declare that they have no competing interests.